Plain-English translation of NCT07285694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which uses your own immune cells that have been specially designed to recognize and attack prostate cancer cells. The cells are taken from your body, modified in the laboratory to help them find cancer, and then given back to you as a single infusion. This medication is experimental and has not yet been approved by the FDA.
Many patients with advanced prostate cancer develop resistance to standard hormone therapies, leaving them with limited treatment options. This trial exists to see whether training your immune system to directly target cancer cells could offer a new way to fight this disease.
You will have cells collected from your blood in a procedure called leukapheresis, which takes a few hours. Your cells will then be sent to a laboratory where they are modified over several weeks. Once ready, you will receive the modified cells back through a single intravenous infusion. After that, you will be followed closely with regular blood tests, scans, and visits to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States